流式细胞术对急性髓系白血病微小残留病的检测及研究进展

霍莹莹; 李艳

doi:10.13201/j.issn.1004-2806.2018.11.017

流式细胞术对急性髓系白血病微小残留病的检测及研究进展

霍莹莹,
李艳^,

- 中国医科大学附属第一医院血液科(沈阳, 110000)

详细信息

通讯作者: 李艳,E-mail:liyan2@medmail.com.cn

中图分类号: R733.71

收稿日期: 2018-01-28

Detection and the progress of the minimal/measurable residual disease in acute myeloid leukemia with the method of flow cytometry

More Information

Corresponding author: , E-mail: liyan2@medmail.com.cn

Received Date: 28 January 2018

摘要

- 流式细胞术 /
- 急性髓系白血病 /
- 微小残留病灶 /
- 风险评估
Abstract: Acute myeloid leukemia（AML）is a series of highly heterogeneous neoplasm,with the development of detections,whose current therapeutic goal is to realize molecular remission to prolong overall survival.Approximately 40% to 65% AML patients will subsequently relapse because of the residual leukemia cells termed minimal/measurable residual disease（MRD）appearing in bone marrow and peripheral blood.The techniques include flow cytometry（FCM）,fluorescence in situ hybridization（FISH）,quantitative real-time polymerase chain reaction（qPCR）,next-generation sequencing technology（NGS）and so on.However,FISH and qPCR can sensitively indentify PML-RARαfusion gene in the diagnosis of 90%acute promyelocytic leukemia（APL）and has been applied to detect MRD widely.While in AML（not including APL）,the methods of MRD are in no agreement.This paper reviews the progress of FCM,the most prevailing detection,in MRD assessment among AML（not including APL）patients.
- flow cytometry /
- acute myeloid leukemia /
- minimal/measurable residual disease /
- risk assessment

HTML全文

参考文献(28)

[1]	DeAngelo DJ,Stein EM,Ravandi F.Evolving therapies in acute myeloid leukemia:progress at last?[J].Am Soc Clin Oncol Educ Book,2016,35:e302-e312.
[2]	翁香琴.《流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识(2016年版)》解读[J].临床血液学杂志,2017,30(9):687-692.
[3]	刘志伟,郭桂凤,韩泽平,等.流式细胞技术在多发性骨髓瘤诊断中的应用研究[J].临床血液学杂志,2017,30(9):714-716.
[4]	Terwijn M,van Putten WLJ,Kelder A,et al.High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia:data from the HOVON/SAKK AML 42A study[J].J Clin Oncol,2013,31:3889-3897.
[5]	Freeman SD,Virgo P,Couzens S,et al.Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia[J].J Clin Oncol,2013,31:4123-4131.
[6]	D hner H,Estey E,Grimwade D,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel[J].Blood,2017,129:424-447.
[7]	Kern W,Haferlach C,Haferlach T,et al.Monitoring of minimal residual disease in acute myeloid leukemia[J].Cancer,2008,112:4-16.
[8]	Ossenkoppele G,Schuurhuis GJ.MRD in AML:does it already guide therapy decision-making?[J].Hematology Am Soc Hematol Educ Program,2016,2016:356-365.
[9]	Paietta E.Should minimal residual disease guide therapy in AML?[J].Best Pract Res Clin Haematol,2015,28:98-105.
[10]	Zeijlemaker W,Kelder A,Oussoren-Brockhoff YJ,et al.Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia[J].Leukemia,2016,30:708-715.
[11]	Zeijlemaker W,Kelder A,Oussoren-Brockhoff YJ,et al.A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia[J].Leukemia,2016,30:439-446.
[12]	Chatterjee T,Mallhi RS,Venkatesan S.Minimal residual disease detection using flow cytometry:Applications in acute leukemia[J].Med J Armed Forces India,2016,72:152-156.
[13]	Roug AS,Larsen HO,Nederby L,et al.hMICL and CD123 in combination with a CD45/CD34/CD117 backbone-a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia[J].Br J Haematol,2014,164:212-222.
[14]	Walter RB,Buckley SA,Pagel JM,et al.Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission[J].Blood,2013,122:1813-1821.
[15]	Rubnitz JE,Inaba H,Dahl G,et al.Minimal residual disease-directed therapy for childhood acute myeloid leukaemia:results of the AML02 multicentre trial[J].Lancet Oncol,2010,11:543-552.
[16]	Walter RB.Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?[J].Curr Opin Hematol,2016,23:102-107.
[17]	Kohnke T,Sauter D,Ringel K,et al.Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse[J].Leukemia,2015,29:377-386.
[18]	Buccisano F,Maurillo L,Spagnoli A,et al.Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia[J].Blood,2010,116:2295-2303.
[19]	Walter RB,Gooley TA,Wood BL,et al.Impact of pretransplantation minimal residual disease,as detected by multiparametric flow cytometry,on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia[J].J Clin Oncol,2011,29:1190-1197.
[20]	Leung W,Pui CH,Coustan-Smith E,et al.Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia[J].Blood,2012,120:468-472.
[21]	Zhou Y,Othus M,Araki D,et al.Pre-and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia[J].Leukemia,2016,30:1456-1464.
[22]	Walter RB,Gyurkocza B,Storer BE,et al.Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation[J].Leukemia,2015,29:137-144.
[23]	Araki D,Wood BL,Othus M,et al.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia:time to move toward a minimal residual disease-based definition of complete remission?[J].J Clin Oncol,2016,34:329-336.
[24]	Schuurhuis GJ,Heuser M,Freeman S,et al.Minimal/measurable residual disease in AML:consensus document from ELN MRD Working Party[J].Blood,2018,131:1275-1291.
[25]	Bene MC,Nebe T,Bettelheim P,et al.Immunophenotyping of acute leukemia and lymphoproliferative disorders:a consensus proposal of the European LeukemiaNet Work Package 10[J].Leukemia,2011,25:567-574.
[26]	Getta BM,Devlin SM,Levine RL,et al.Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation[J].Biol Blood Marrow Transplant,2017,23:1064-1071.
[27]	Zhao X,Yan C,Liu D,et al.Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity[J].Ann Hematol,2013,92:1111-1119.
[28]	邱林.未来精准治疗白血病的卫士——新一代高通量测序技术[J].临床血液学杂志,2017,30(5):342-344,349.